JP2006515607A - 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少 - Google Patents

泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少 Download PDF

Info

Publication number
JP2006515607A
JP2006515607A JP2006500313A JP2006500313A JP2006515607A JP 2006515607 A JP2006515607 A JP 2006515607A JP 2006500313 A JP2006500313 A JP 2006500313A JP 2006500313 A JP2006500313 A JP 2006500313A JP 2006515607 A JP2006515607 A JP 2006515607A
Authority
JP
Japan
Prior art keywords
tolterodine
pharmaceutically effective
antimuscarinic agent
use according
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515607A5 (https=
Inventor
バーバラ・エイチ・コーバーリイ
スーザン・エム・デインハウアー
Original Assignee
ファイザー・ヘルス・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006515607(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファイザー・ヘルス・アクチエボラーグ filed Critical ファイザー・ヘルス・アクチエボラーグ
Publication of JP2006515607A publication Critical patent/JP2006515607A/ja
Publication of JP2006515607A5 publication Critical patent/JP2006515607A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006500313A 2003-01-22 2004-01-14 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少 Pending JP2006515607A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22
PCT/IB2004/000169 WO2004064821A1 (en) 2003-01-22 2004-01-14 Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders

Publications (2)

Publication Number Publication Date
JP2006515607A true JP2006515607A (ja) 2006-06-01
JP2006515607A5 JP2006515607A5 (https=) 2006-12-28

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500313A Pending JP2006515607A (ja) 2003-01-22 2004-01-14 泌尿器障害を治療するためのトルテロジン及び他の抗ムスカリン様作用剤の用量の減少

Country Status (17)

Country Link
US (2) US20060047007A1 (https=)
EP (1) EP1589958B2 (https=)
JP (1) JP2006515607A (https=)
KR (1) KR20050096147A (https=)
CN (1) CN1741796A (https=)
AT (1) ATE432070T1 (https=)
AU (1) AU2004206110A1 (https=)
BR (1) BRPI0406861A (https=)
CA (1) CA2514022C (https=)
DE (1) DE602004021233D1 (https=)
ES (1) ES2324712T5 (https=)
IL (1) IL169362A0 (https=)
MX (1) MXPA05007767A (https=)
PL (1) PL377995A1 (https=)
TW (1) TW200418447A (https=)
WO (1) WO2004064821A1 (https=)
ZA (1) ZA200505026B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
ES2322148T3 (es) * 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
PT1986642E (pt) * 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
JP2000515525A (ja) 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
NZ518309A (en) * 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours

Also Published As

Publication number Publication date
ES2324712T5 (es) 2012-06-08
TW200418447A (en) 2004-10-01
BRPI0406861A (pt) 2006-01-03
DE602004021233D1 (de) 2009-07-09
ES2324712T3 (es) 2009-08-13
CN1741796A (zh) 2006-03-01
KR20050096147A (ko) 2005-10-05
EP1589958B1 (en) 2009-05-27
WO2004064821A1 (en) 2004-08-05
ZA200505026B (en) 2006-07-26
CA2514022C (en) 2010-07-13
ATE432070T1 (de) 2009-06-15
CA2514022A1 (en) 2004-08-05
PL377995A1 (pl) 2006-02-20
US20060047007A1 (en) 2006-03-02
US20070155838A1 (en) 2007-07-05
MXPA05007767A (es) 2006-01-31
AU2004206110A1 (en) 2004-08-05
EP1589958A1 (en) 2005-11-02
EP1589958B2 (en) 2012-04-11
IL169362A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
Clemett et al. Tolterodine: a review of its use in the treatment of overactive bladder
Farrell et al. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression
JP4249415B2 (ja) Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
DE602004003172T2 (de) Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP1572181B1 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen
EP3272343B1 (en) Tapentadol for preventing and treating depression and anxiety
JP2019131598A (ja) タペンタドールの用量調節
Biastre et al. Trospium chloride treatment of overactive bladder
Epstein et al. Newer agents for the management of overactive bladder
US20070155838A1 (en) New Method for Treating Urinary Disorders
Michel A benefit-risk assessment of extended-release oxybutynin
EP0506384A1 (en) Pharmaceutical composition for the treatment of urinary incontinence containing DL- or L-threo-3-(3,4-dihydroxyphenyl)serine
Comer et al. Extended-release oxybutynin
EP1682110A1 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem alpha agonisten
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
KR102927058B1 (ko) 진통 가려움 완화 약학 조성물 및 그 응용 방법
JP2024534173A (ja) 睡眠時無呼吸を治療するための方法及び組成物
US11654133B2 (en) Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy
US8901177B2 (en) Method of treating bladder disorders
Kuteesa et al. Anticholinergic drugs for overactive bladder
AU2015305430A1 (en) Method for treating hyperhidrosis
HK1084028A (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
WO2025106773A1 (en) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
Pradhan et al. Recommended management of female urinary incontinence
Majmudar et al. Current drug treatments for female urinary incontinence

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061109

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090210

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524